We examined how well differentially expressed genes and multigene outcome classifiers retain their classdiscriminating values when tested on data generated by different transcriptional profiling platforms. RNA from 33 stage I-III breast cancers was hybridized to both Affymetrix GeneChip and Millennium Pharmaceuticals cDNA arrays. Only 30% of all corresponding gene expression measurements on the two platforms had Pearson correlation coefficient r > 0.7 when UniGene was used to match probes. There was substantial variation in correlation between different Affymetrix probe sets matched to the same cDNA probe. When cDNA and Affymetrix probes were matched by basic local alignment tool (BLAST) sequence identity, the correlation increased substantially. We identified 182 genes in the Affymetrix and 45 in the cDNA data (including 17 common genes) that accurately separated 91% of cases in supervised hierarchical clustering in each data set. Cross-platform testing of these informative genes resulted in lower clustering accuracy of 45 and 79%, respectively. Several sets of accurate five-gene classifiers were developed on each platform using linear discriminant analysis. The best 100 classifiers showed average misclassification error rate of 2% on the original data that rose to 19.5% when tested on data from the other platform. Random fivegene classifiers showed misclassification error rate of 33%. We conclude that multigene predictors optimized for one platform lose accuracy when applied to data from another platform due to missing genes and sequence differences in probes that result in differing measurements for the same gene. 
Transcriptional profiling is increasingly explored as a potential diagnostic tool in an attempt to classify cancer into clinically relevant subgroups or predict disease outcome. 1 In the gene expression profiling literature, prediction of clinical outcome is usually made based on the constellation of a relatively large numbers of genes. Comparison of prediction results across several laboratories is critically important to determine the practical value and technical limitations of a proposed new test. Cross-laboratory validation of gene expression-based predictors is challenging. Different laboratories frequently use different microarray platforms that usually contain different sets of genes. Different platforms may also measure the expression of the same gene with different precision, on a different scale and with different dynamic range. [2] [3] [4] When a gene signature-based predictor discovered in one laboratory is tested on cases at a different laboratory, poorer predictive performance may result from at least two major factors. The first is biological; a predictor developed from a particular set of clinical specimens may not be generalizeable to a different set of cases. This is more likely to occur if the sample size used for marker discovery is too small. The second factor is technical; predictors generated from data obtained with one platform may become compromised when applied to data generated by another platform. This could be due to missing informative genes or to measurement differences. Different gene expression profiling platforms measure the expression of the same gene with different relative accuracy on a different numerical scale.
The goal of the current research was to compare gene expression data generated by Affymetrix UB3A (Santa Clara, CA) oligonucleotide arrays with those generated by cDNA microarrays from the same 33 RNA samples extracted from fine-needle aspirates of breast cancer. We examined three questions. 1) How closely do normalized gene expression measurements for the same gene correlate across platforms? 2) Do genes that discriminate between responders and nonresponders to chemotherapy in hierarchical cluster analysis on one platform retain discriminating value when tested on data generated by another platform? 3) How well do multigene predictors generated on one platform hold up on data generated by the other platform? Because the same RNA was profiled on both platforms, this design allowed us to evaluate the impact of the profiling method without the confounding effect of sampling variation. This analysis was not designed to compare the accuracy of the two platforms. This would have required a third, external, gold standard measurement of mRNA expression. Similarly, our goal was not to develop the best possible predictor of pathological CR from this data. This would have required a somewhat different statistical approach to optimize the predictor for validation on independent samples.
Materials and Methods

Patients and Samples
Fine-needle aspiration (FNA) specimens from 33 patients with newly diagnosed stage I-III breast cancer were included in the cross-platform analysis. These cases were selected from an ongoing clinical trial at the University of Texas M.D. Anderson Cancer Center, and patient characteristics are presented in Table 1 . The study was approved by the Institutional Review Board (IRB) of the University of Texas M.D. Anderson Cancer Center, and all patients signed an informed consent. The goal of the larger trial is to develop a multigene predictor of pathological complete response to preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy. Early results of this response marker discovery project were reported separately. 5 The cases included in the current analysis were selected because they had gene expression profiling performed on two different platforms. This was done as part of a transition from limitedsupply, proprietary, cDNA nylon membrane arrays (Millennium Pharmaceuticals, Inc., Cambridge, MA) to the commercially available Affymetrix oligonucleotide DNAchip platform. Twenty-seven additional specimens that were collected consecutively were included in a small independent validation of the performance of the classifier that performed well on both platforms.
All FNAs were obtained before any systemic therapy and were collected into vials containing RNAlater solution (Ambion, Austin, TX) and stored at Ϫ80°C until profiling. The RNA yield and cellular composition of these samples have previously been reported. 6 Estrogen receptor (ER) and HER-2 receptor status of each cancer was assessed on a separate diagnostic core biopsy as part of routine care. ER was assessed by immunohistochemistry using 1D5 antibody from Zymed (San Francisco, CA).
Microarray Hybridization
RNA was extracted from FNA samples using the RNAeasy kit (Qiagen, Valencia, CA). The amount and quality of RNA was assessed with a DU-640 U.V. Spectrophotometer (Beckman Coulter, Fullerton, CA) and by an Agilent 2100 Bioanalyzer RNA 6000 LabChip kit (Agilent Technologies, Palo Alto, CA). Two microarray platforms were tested in this study: the Affymetrix Human Genome U133 A and B gene chip sets and cDNA nylon membranes proprietary to and printed by Millennium Pharmaceuticals. The cDNA arrays contained 21,594 independent human sequence-verified clones. For the cDNA array hybridization, first-strand cDNA synthesis was performed with Superscript II (Invitrogen, Carlsbad, CA) in the presence of [ 33 P]dCTP (100 mCi/ml; Amersham, Little Chalfont, UK) from 1 to 2 g of total RNA. The isotopelabeled cDNA probes were hybridized without further amplification to high-density nylon arrays. Affymetrix profiling was also performed without second round amplification following the standard protocol using 1 g of total RNA from the same pool used for the cDNA array experiments. Briefly, double-stranded cDNA was synthesized, followed by in vivo transcription reaction to generate biotinylated cRNA. Biotin-labeled and fragmented cRNA was hybridized to the Affymetrix U133A and B gene chips overnight at 42°C. Procedures followed standard operating practice outlined in the Affymetrix technical manual. The Affymetrix GeneChip system was used for hybridization and scanning of the probe arrays, and Microarray Analysis Suite (MAS) 5.0 was used for data acquisition.
Data Processing
Results of the cDNA membrane array experiments and data acquisition were previously reported. 7 Gene expression values of the cDNA array experiments were normalized to the median expression value of all genes on each membrane array. The median values were set to 1 by the normalization process; the postnormalization mean expression values ranged from 2.535 to 4.787. For the Affymetrix data, several standard metrics were examined to assess the quality of each hybridization result. We assessed T7 amplification and labeling efficiency by calculating the 3Ј to 5Ј ratios of ␤-actin and glyceraldehyde-3-phosphate dehydrogenase. The median ratio for ␤ actin was 1.45 (range, 1.21 to 1.60); for glyceraldehyde-3-phosphate dehydrogenase, 1.13 (range, 0.86 to 1.67). To assess brightness, we used dCHIP V1.3 to calculate the percentages of array outliers and of single outliers for each chip. 8 MAS 5.0 was used to produce P values for signal detection. Chips with more than 5% array or single outliers or with less than 15% detection P values Ͻ0.01 were flagged. All 33 Affymetrix profiles included in this analysis have passed each QC step. Affymetrix data were quantified and normalized with dCHIP V1.3 (http://biosun1.harvard.edu/complab/dchip). 8 
Statistical Analysis
The primary goal of this research was cross-platform testing of informative genes and multigene outcome predictors in an experimental setting in which the only variable is the gene expression profiling technique. Normalized expression data from both platforms was transformed by computing the base-two logarithm before further analysis. Pearson correlation coefficients were calculated on the normalized, log-transformed data for each gene represented on both platforms, with matching based on UniGene build 160. Further analysis was performed only on the subset of genes shared on both the Affymetrix and cDNA platforms. When multiple cDNA probes or Affymetrix probe sets targeted the same gene, separate Pearson and Spearman correlation coefficients were calculated for each distinct probe set and matching cDNA probe. The distribution of all gene expression measurements on both platforms was near normal. To identify differentially expressed genes between the two response outcome groups, pathological complete response versus residual cancer, we explored two methods: the two-sample t-test and an unequal variance t-test on the ranks. The resulting P values were analyzed as a ␤-uniform mixture, and the relationship between P values and false discovery rate (FDR) was assessed. 9, 10 Hierarchical clustering was performed using the informative genes identified in the univariate analysis. The distance metric was computed on log-transformed gene expression values. Data analyses were performed using the statistical software package S-Plus 2000 (Insightful Corp., Seattle, WA).
Multigene classifiers were built by combining a genetic algorithm (GA) with linear discriminant analysis (LDA). 11, 12 This classification strategy consists of two main components. The GA is used as a gene selector to identify the best combination of discriminating genes, and the class prediction is performed by LDA. The working and optimization principle of GA is analogous to an evolutionary process and does not rely on rank-based gene selection as a t-test does. 11 This method has previously been applied successfully to high-dimensional gene expression and proteomic profile data. [13] [14] [15] [16] A potential advantage of this approach is that the GA can identify combination of genes that are predictive together even if individual genes that contribute to the classifier have limited predictive value and would be missed by two-sample t statistics. However, to reduce computation time, we performed GA/LDA on a subset of the data that was enriched in informative genes. The subsets in each platform were selected based on the FDR computed from the two-sample t-tests. By setting FDR Ͻ 0.6, we selected 1032 clones on the cDNA platform and 2010 probe sets on the Affymetrix platform. This preselection of genes was performed to reduce computation time by using genes with somewhat increased class-discriminating value. Twenty-seven cases were used as an independent validation set to test the predictive accuracy of the predictor that had the highest cross-validation accuracy on both platforms.
Results
Identification of Shared Genes Present on Both the Affymetrix U133 A/B Chips and the cDNA Membrane Arrays
We used GenBank accession numbers to identify matching genes on both platforms (UniGene build 160, Spring 2003). The U133A chip contained 22,215 probe sets representing 13,736 unique UniGene clusters, and the U133B chip contained 22,577 probe sets representing 17,132 unique UniGene clusters. The cDNA nylon membranes contained 30,720 clones corresponding to 21,594 unique UniGene clusters. We found 9402 unique UniGene clusters that overlapped between the U133A chip and the nylon cDNA array (corresponding to 14,897 probe sets on the U133A chip and to 14,104 clones on the cDNA array). We also found 8430 clusters that overlapped between the U133B chip and the cDNA arrays (corresponding to 11,472 probe sets on the U133B chip and to 12,079 clones on the cDNA array). Figure 1 illustrates these results.
Correlation of Gene Expression Measurements between Affymetrix and cDNA Data
We calculated the Pearson correlation coefficients of corresponding gene expression measurements for the genes represented on both platforms using normalized log-transformed data. Of the 24,100 individual matching probe set measurements, 3232 had a Pearson correlation coefficient r Ն 0.7, another 7590 measurements had r Ն 0.5, and 12,466 measurements had an r Ն 0 but Յ 0.5. There were 4044 measurements that had negative correlation coefficient. The distribution of all Pearson coefficients indicated a modest overall correlation of individual gene expression measurements across the two platforms ( Figure 2A ). Similar results were seen when Spearman correlation coefficient was used (data not shown). Concordance correlation of t scores for the matching probes on the two platforms was also modest, r ϭ 0.458. Closer examination of the two data sets revealed that the U133A often contains multiple probe sets corresponding to a particular gene on the cDNA platform. Of the 9402 shared genes on U133A chip and on the cDNA array, only 4309 had a 1:1 ratio of probe sets to cDNA clones. When multiple probe sets with distinct sequences targeted the same gene, substantial differences in correlation with the corresponding cDNA array measurement were seen. Some probe sets displayed very high correlation, whereas others showed minimal or no correlation with the cDNA result. To further address this problem, we performed BLAST sequence match for each paired cDNA clone and Affymetrix probe set. cDNA clone sequences and the Affymetrix 25-mer probes were aligned against the National Center for Biotechnology Information Reference Sequences (RefSeq) of each target gene. If both the cDNA clone and the Affymetrix probe had Ն25 nucleotides overlapping with the RefSeq sequences, then the pair was considered "RefSeq-matched" using software bl2seq. Three categories of probe pairs were created: 1) probes pairs that targeted the same gene but were misaligned and shared no overlap in RefSeq target sequence (n ϭ 2108), 2) pairs that matched to the same RefSeq sequence as described above (n ϭ 3169), and 3) pairs where cDNA and Affymetrix probe sequences directly overlapped (n ϭ 4008). As expected, closer se- 360 Stec et al JMD August 2005, Vol. 7, No. 3 quence matches between the cDNA and Affymetrix probes yielded greater correlation. Figure 2B illustrates the distribution of Pearson correlation coefficient for the Affymetrix and cDNA probe pairs that had direct sequence overlap.
These results suggest that DNA microarray-based gene expression measurements are in fact robust and reproducible across platforms if the probe sets have overlapping sequences. However, this includes only a relatively small percentage of all probes present on these two particular array platforms, 29% (Affymetrix U133A) and 19% (Millennium Pharmaceuticals cDNA arrays), respectively.
Sequence-Based Explanation for the Discrepant Expression Measurements on the Two Platforms
To illustrate the impact of sequence matching and location of Affymetrix probe target sequence in relation to the 3Ј end of the transcript, we examined the expression results for the ER obtained with the two platforms. The expression of estrogen ER is routinely measured in breast cancer specimens by immunohistochemistry. ER protein expression correlates closely with mRNA expression of ER. 7, 17 These routine clinical results, which were available for all cases, provided an external "gold standard" reference for ER expression. We observed very good correlation between ER expression determined by immunohistochemistry and by cDNA microarray (estrogen receptor 1␣, IMAGE clone 725321, Hs.1657; NM_000125) or by Affymetrix gene chip when the probe set "205225_at" was used for comparison. The expression values of ER measured by cDNA arrays and by the Affymetrix probe set "205225_at" also correlated with each other very highly (r ϭ 0.976). However, there are multiple probe sets that target the human ER ␣ gene on the Affymetrix U133A chip. The correlation coefficients of these probe sets with the ER cDNA result (and with the gold standard immunohistochemistry (IHC) result) varied considerably, ranging from 0.146 to 0.976 (Figure 3) . The normalized mean expression intensities of these ER probe sets were also highly variable, ranging from 62 to 1291 (arbitrary units).
We examined the sequence and structure of the human ER ␣ gene in relation to the IMAGE clone ER sequence represented on the cDNA array and the various Affymetrix oligonucleotide ER probe sequences. The closer the region of an Affymetrix probe set was to the region of the IMAGE clone, the higher the correlation was between the two measurements ( Figure 3 ). Probe set "205225_at" had direct sequence overlap with the cDNA probe sequence and showed the highest correlation and greatest signal intensity. For probe sets "211233_x_at" and "215552_s_at", the correlation with the cDNA measurement was still strong, but the signal intensities were less than one-tenth of the signal produced by probe set "205225_at". This may be explained by the distance of these sequences from the 3Ј end of the ER transcript. The target sequence for "205225_at" is located at the 3Ј end of the transcript in a long untranslated region; the other two probes are located closer to the 5Ј end, and there are 3500 nucleotides between probe set 205225_at and the other two probes with lesser signal intensity. Considering that the reverse transcription reaction starts at the 3Ј end, a bias favoring the 3Ј end of the cDNA among the labeled probes is expected. However, additional mechanisms cannot be excluded. Alternative poly-A addition is a possibility, especially for very long untranslated regions. Also, the presence of ER transcript variants in human breast cancers could contribute to lower intensity values for these probes. GenBank sequences S80316 or AF258449/AF258450 are possible ER variants that lack exons corresponding to at least parts of probe sets "215552_s_at" and "211233_x_at".
The lack of correlation of probe set "215551_at" with ER gene expression may also be explained by the peculiarities of that sequence. This sequence maps to an exon that is only reported in one ER-related expressed sequence tag sequence. This raises the possibility of an alternative 3Ј end that gives rise to a shorter ER transcript variant. The lack of correlation with the cDNA result and with the clinical ER status coupled with the low signal intensity for this particular probe suggest a low-abundance ER transcript variant that could be expressed at low levels uniformly in all samples. These observations suggest that the relatively poor overall correlation between the cDNA array and Affymetrix results is largely due to sequence differences between the probes present in the two platforms.
Do Informative Genes Identified on One Platform Retain Their Discriminating Function on Another Platform in Hierarchical Cluster Analysis?
We identified genes that were differentially expressed between the 10 cases with pathological complete response (pCR) and the remaining 23 cases that had residual cancer (RD) after completion of preoperative chemotherapy (Supplementary Table S1 , A and B at http:// jmd.amjpathol.org/). In the cDNA array data, we used unequal variance t-test on the ranks to identify 45 genes as differentially expressed each with P Յ 0.00236 that corresponded to FDR Յ 0.40. This high false discovery rate suggested that the most informative genes on the cDNA platform were removed when analysis was restricted to probes that had a matched pair on the U133A chip. However, high FDR rate was acceptable for our purpose because we wanted to identify a large number of discriminating genes in this particular data and to test how well their discriminating value holds up when tested on expression data generated from the same RNA with a different profiling platform. One approach to test the discriminating value of these genes is to perform supervised hierarchical clustering with these informative genes. Average linkage supervised hierarchical clustering of the cDNA array data using these 45 genes visually demonstrated that these genes had high discriminating value on the original data set, with 10 pCR/3 RD in one main cluster and 0 pCR/20 RD in the other that represents a 91% overall clustering accuracy (Figure 4 ). When the same 45 genes, corresponding to 62 Affymetrix probe sets, were used to cluster the Affymetrix data, the genes lost a substantial amount of discriminating value. Six cases of pCR and three RD clustered together in one main arm of the dendrogram and 4 pCR/20 RD were in the other main cluster, representing a 79% overall clustering accuracy. This decrease in discriminating value was predicted based on the modest overall correlation of individual gene expression values on the two platforms.
Applying the same selection criterion (FDR Յ 0.40) to the Affymetrix data yielded 182 probe sets corresponding to 166 distinct genes each with P Յ 0.00607. When these genes were used for supervised hierarchical clustering, they also performed well on the original data. Eight cases of pCR and 1 case of RD were clustered in one main cluster and 2 pCR and 22 RD formed the other main cluster (91% clustering accuracy). However, when the same 166 genes (corresponding to 249 cDNA clones) were used to cluster the cDNA data, a practically complete loss of discriminating value was seen (data not shown).
These results indicate that informative genes identified on one gene expression profiling platform lose some of their class-discriminating value when measured with a different profiling method. This is further illustrated by the observation that only 17 genes were common to the cDNA and Affymetrix differentially expressed gene lists generated from the same cases ( Table 2) . As expected, the correlation coefficients for these 17 genes across the platforms were high. When these 17 genes common to both lists were used for hierarchical clustering, almost all cases of pathological CR clustered together in both types of expression data. It was, therefore, possible to identify genes and probe sets that retained discriminating value across platforms by using only genes that show high correlation coefficients when measured by the two distinct platforms. Such genes may be identified by sequence matching of the probes. Hierarchical clustering is not a class prediction tool, and assignment of molecular class or expected outcome to new cases based on dendogram results is not appropriate. There are several mathematical methods that are better suited to formulate outcome predictions based on the constellation of multiple genes.
Multigene Classifiers of Response to Therapy Generated on One Platform Show Diminished Classification Accuracy When Applied to Data Obtained with Another Platform
We used a genetic algorithm (for gene selection) in combination with linear discriminant analysis (for class prediction) to develop a large number of multigene classifiers that could separate cases with pathological CR from those with residual disease within each data set. As a preliminary step, we used a variant of the "greedy" algorithm method to determine how many genes should be permitted in the classifiers. To begin, we selected the gene with the largest (absolute) t score and next computed the Mahalanobis distance between the two groups using every pair of genes. The pair with the largest Ma- halanobis distance was then included in the LDA classifier, and the classification accuracy was calculated. If the classification accuracy was improved, then this gene was added to the classifier. We repeated this process, adding additional genes until the classification accuracy stopped improving. On both platforms, the algorithm terminated at five genes. Five-gene LDA classifiers could perfectly separate pathological CR from RD in each data set. We ran the GA on data from each platform to identify 100 different sets of five genes that in combination with the LDA class prediction algorithm showed the best predictive accuracy. This analysis yielded 100 different GA/ LDA classifiers that could be tested on the original data and on the data from the other platform. The 100 sets of five-gene classifiers built from the cDNA data misclassified on average 0.69 cases, corresponding to 2% misclassification error rate (MER), on the original platform. Forty-eight of the 100 sets yielded 0 misclassifications. Thirty-seven sets yielded 1 and 13 sets yielded 2 misclassifications ( Figure 5 ). When these 100 predictors developed from the cDNA data were tested on the Affymetrix results, the classification accuracy dropped. The average number of misclassified cases was 6.42 corresponding to 19.5% average MER. No set produced perfect classification when tested on the Affymetrix results, and only four sets yielded Յ2 misclassified cases ( Figure 5) . However, the cross-platform classification performance of these predictors (optimized for the cDNA results) was still better than that observed with random predictors. We tested the performance of LDA with 100 randomly selected five-gene sets from the cDNA data. The average number of misclassified cases was 10.88 (33% average MER) on the cDNA platform and 9.62 (29% average MER) on the Affymetrix data.
We repeated the same analysis using the Affymetrix results for developing five-gene predictors. The performance of these predictors showed similar characteristics to what was observed with the cDNA-based predictors. The average number of misclassified cases was 1.2 (3.6% average MER) on the Affymetrix platform and 5.13 (15.5% average MER) on the cDNA data. The 100 sets of random Affymetrix predictors yielded an average of 11.43 (34.6% average MER) and 9.65 (29.2% average MER) misclassified cases on each platform, respectively.
When we compared the two sets of 100 five-gene classifiers identified from the cDNA and Affymetrix data, respectively, we could identify only three classifiers that were common and therefore performed well on both platforms. The classifier that performed the best on both platforms included the following five genes: PPFIBP2 (Hs. 364 Stec et al JMD August 2005, Vol. 7, No. 3 sified one case on the cDNA and two cases on the Affymetrix platforms.
Assessment of the Predictive Accuracy of the Best Five-Gene Classifier on Independent Cases
A predictor that consists of a handful of genes that are reliably and comparably measured by both Affymetrix and cDNA platforms could be very useful, particularly if it predicts outcome accurately in new cases. To estimate the true predictive accuracy of the five-gene LDA predictor that performed the best on both platforms, we tested it on an independent set of 27 patients profiled on Affymetrix. The classifier showed a 70% overall prediction accuracy (95% CI ϭ 50%, 86%). This suggests that it may be possible to develop multigene predictors that perform well across platforms and also show reasonably good predictive accuracy in independent cases.
It is important to consider that the five-gene LDA predictor examined in this analysis may not be the best of all possible predictors that can be developed from each particular data set. Many of the most informative genes (in univariate analysis) in the Affymetrix data were not represented on the cDNA arrays and vice versa. Also, there are a large number of supervised classification methods including support vector machines, k-nearest neighbor, and various types LDA algorithms that can be used to generate predictors. The comparison of different classification methods and selection of the optimal predictor for independent validation was not the main goal of this study, and it is the subject of a separate analysis that includes larger number of cases.
Discussion
More and more laboratories explore gene expression profiling with DNA microarrays as a potential diagnostic tool for classification of cancer. There are a large number of different profiling platforms available for research including commercially available arrays like Affymetrix gene chips and various proprietary and custom-made cDNA and oligonucleotide arrays. Some platforms may only be available at the single laboratory that has assembled it. It is integral to the scientific process to evaluate the performance of novel gene expression-based classifiers in different laboratories and on independent data sets. However, this cross-laboratory validation often involves cross-platform testing. The performance of any classifier in this type of cross-platform and cross-sample validation depends on 1) how generalizeable the initial observation is, and 2) how closely the gene expression measurements of the discriminating genes correspond to each other on the different platforms. Even an accurate outcome predictor may show limited cross-platform reproducibility if the two platforms do not measure the informative, discriminating genes similarly.
We examined the concordance between gene expression data generated from the same RNA specimens by two different DNA microarray platforms. One platform, Millennium Pharmaceuticals cDNA arrays, contained 21,594 unique UniGene clusters; the Affymetrix HU133 A and B chips contained 30,868 clusters. Only 17,832 clusters were present on both platforms. We observed modest overall correlation between paired measurements of the same genes when probes were matched by UniGene. This was apparent regardless of the correlation metric used including Pearson and Spearman correlation coefficients or Concordance correlation of t scores. Our findings are consistent with several other reports that indicated modest overall correlation of gene expression measurements across platforms. 18 -20 Some Affymetrix probe sets displayed very high correlation with matching cDNA array results, but other probe sets targeting the same gene showed minimal or no correlation. We hypothesized that this variable correlation may be partly due to sequence differences between the cDNA probes and the various Affymetrix probe sets and the location of the target sequence within the gene to be measured. In the case of the ER gene, we could demonstrate that both arrays could measure the expression of ER very accurately compared with an external clinical gold standard and in a highly concordant manner. However, each ER probe set present on the U133A chip showed different levels of expression intensities and various degrees of correlation with ER gene expression defined by IHC or cDNA array. These differences in expression intensity could be explained by the location of the oligonucleotide target sequences within the ER cDNA. When we examined the correlation between cDNA and Affymetrix probes that had direct sequence overlap, the correlation was quite high. Most of the discrepant correlations between Affymetrix probe sets and cDNA measurements could be explained by the sequence differences of the probes. Important factors that contribute to the different signal intensities generated by distinct probes that target the same gene at different locations include differing GC-content, sequence length, intraplatform cross-match opportunities, and the location of the probe sequence in relation to the 3Ј end. 18 Because many microarray studies draw their conclusions from hierarchical clustering analyses, cross-platform preservation of clustering results is important. We examined whether genes that are differentially expressed between tumors that had complete pathological response to preoperative chemotherapy and those with residual cancer retain their class-discriminating value when used in supervised hierarchical clustering across platforms. Dendograms should be similar if intraplatform relationships between measurements are similar on the two different platforms. Because only 68% of the Affymetrix U133A chip and 44% of the cDNA array genes were common to both platforms, to avoid complexities due to missing informative genes, we restricted our analysis to select differentially expressed genes from the subset of genes represented on both platforms (n ϭ 9402). There was only limited overlap between the lists of informative genes that distinguished cases with pathological CR from those with residual disease generated from the same samples with two different profiling plat-forms. Only 17 genes were common to the 45-gene long cDNA and 168-gene long Affymetrix lists. Not surprisingly, informative genes performed well in supervised hierarchical clustering on the original data but showed decreased discriminating value when applied to data generated on the other platform.
We also examined the cross-platform performance of 100 sets of five-gene GA/LDA response predictors. The average misclassification error rate of these five-gene classifiers developed from the cDNA data were 2% on the original data. When the same classifiers were tested on the Affymetrix data, the average misclassification error rate has risen to 19.5%. For comparison, five-gene random classifiers produced 33% average misclassification error rates. Essentially identical results of diminished classification accuracy were observed when classifiers developed from the Affymetrix data were applied to cDNA results.
It is important to recognize that we compared two very different profiling platforms, cDNA nylon arrays hybridized to radioactive-labeled samples versus oligonucleotide Affymetrix GeneChips hybridized to biotin-labeled samples. Platforms that are more similar, for example two different versions of Affymetrix GeneChips, may show greater concordance of results because of greater similarity of the probe sequences. We only examined the performance of supervised hierarchical clustering and class (response outcome) prediction based on linear discriminant analysis, therefore it is possible that other class prediction methods may be more robust for crossplatform application. However, there is no reason to believe that any prediction algorithm would perform well across platforms if the concordance between the expression measures of the informative genes is low. Essentially all published results that attempted cross-platform testing of informative genes regardless of class prediction methodology reported diminished (but not completely lost) classification accuracy on data generated by platforms other than the original platform. 21, 22 In summary, many genes with class-discriminating value on one profiling platform lose some of their discriminating value when measured with another profiling method. It is possible to select a subset of genes that retain much of their class-discriminating value across platforms based on high degree of sequence overlap between the probes. However such paired probes represent only a small minority of all probes present in any particular platform. Although it is reassuring that multigene predictors do hold up to some extent when applied across platforms, cross-platform application of multigene classifiers may have limited clinical value because of substantial and unpredictable loss of classification accuracy due to 1) missing informative genes and 2) often suboptimal measurement of informative genes between platforms. These observations underscore the importance of collaborative efforts to create uniform gene expression databases across various laboratories using standard operating procedures and a common platform to test the true diagnostic potential of this technology.
